Potential Use of Extracellular Vesicles for the HER2 Status Assessment in Breast Cancer Patients
Genes, Chromosomes and Cancer · 2024
DOI: 10.1002/gcc.23264 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes, Chromosomes and Cancer, 2024. Verfasst von Sol Moon und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Yonsei University College of Medicine, Seoul, South Korea. Hauptthemen laut MEDLINE: Breast Neoplasms, Extracellular Vesicles, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Research Foundation of Korea.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Human epithelial growth factor receptor 2 (HER2)‐targeted therapies are effective in patients with HER2‐positive breast cancer. Recent advances have shown that HER2‐targeted therapies can also be of benefit when treating tumors expressing low levels of HER2, highlighting the importance of identifying the HER2‐low subgroup. This clinical trend has opened new therapeutic avenues for patients who were previously ineligible for HER2‐targeted therapies. Thus, the development of new diagnostic methods for real‐time HER2 profiling is crucial for accurately tailoring the treatment for these patients. We hypothesized that tumor‐derived extracellular vesicles (TEVs) could reflect the HER2 profiles of primary tumors and potentially serve as diagnostic tools for HER2 status. This approach was validated using six breast cancer cell lines, which confirmed that the TEVs accurately reflected the HER2 profiles of the tumor cells. TEVs were isolated using an immunoaffinity method, and copy number variation (CNV) in the ERBB2/EIF2C ratio was assessed using droplet digital PCR of DNA from these vesicles. Clinical validation using plasma samples from 33 breast cancer patients further reinforced the diagnostic potential of our method. Pearson's correlation coefficient analysis of the flow cytometry results demonstrated that TEVs reflected HER2 expression in primary cells. To distinguish between HER2‐negative and HER2‐low patients, the area under the curve (AUC) of the ROC curve in our method was 0.796, with a sensitivity of 53.8% and a specificity of 100%. These findings suggest the clinical utility of extracellular vesicles derived from plasma and emphasize the need for further research to distinguish HER2‐negative from HER2‐low patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Yonsei University College of Medicine, Seoul, South Korea.
ORCID-Profile: Sol Moon, Seung Il Kim, Suji Lee, Hyojung Lee, Young Kim, Joon Ye Kim, Min Woo Kim, Jee Ye Kim
Förderung
- National Research Foundation of Korea
Zitieren
APA
Moon, S., Kim, S. I., Lee, S., Lee, H., Kim, Y., Kim, J. Y., Kim, M. W., & Kim, J. Y. (2024). Potential Use of Extracellular Vesicles for the HER2 Status Assessment in Breast Cancer Patients. Genes, Chromosomes and Cancer. https://doi.org/10.1002/gcc.23264
Vancouver
Moon S, Kim SI, Lee S, Lee H, Kim Y, Kim JY, et al. Potential Use of Extracellular Vesicles for the HER2 Status Assessment in Breast Cancer Patients. Genes, Chromosomes and Cancer. 2024. doi:10.1002/gcc.23264
BibTeX
@article{Moon2024,
author = {Moon, Sol and Kim, Seung Il and Lee, Suji and Lee, Hyojung and Kim, Young and Kim, Joon Ye and Kim, Min Woo and Kim, Jee Ye},
title = {Potential Use of Extracellular Vesicles for the HER2 Status Assessment in Breast Cancer Patients},
journal = {Genes, Chromosomes and Cancer},
year = {2024},
doi = {10.1002/gcc.23264}
}
EUVIMED